Aerie Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 36.13 million compared to USD 29.31 million a year ago. Net loss was USD 26.83 million compared to USD 39.69 million a year ago. Basic loss per share from continuing operations was USD 0.56 compared to USD 0.86 a year ago. Diluted loss per share from continuing operations was USD 0.56 compared to USD 0.86 a year ago.
For the nine months, revenue was USD 99.28 million compared to USD 79.47 million a year ago. Net loss was USD 82.09 million compared to USD 120.34 million a year ago. Basic loss per share from continuing operations was USD 1.72 compared to USD 2.6 a year ago.